Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMUM: Ixazomib and Lenalidomide in Multiple Myeloma
NCT03941860Phase 3Completed
- Sponsor
- National Cancer Institute
- Start
- Feb 2022
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in multiple myeloma (MM) comparing Ixazomib + Lenalidomide with Placebo + Lenalidomide (2 arms). Primary endpoint: Overall Survival up to 10 years. Started Feb 2022; status: completed.
02
Drugs
ixazomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03941860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03941860.